Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) have announced a strategic manufacturing partnership for biosimilars. Under the agreement, OneSource will provide integrated Drug Substance and Drug Product manufacturing from its biologics facility in Bangalore, India, supporting Formycon's biosimilar programs for global markets. The collaboration combines Formycon's biosimilar development expertise with OneSource's end-to-end biologics manufacturing capabilities.
Dr. Stefan Glombitza, CEO of Formycon AG, stated: 'Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.'
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, added: 'We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics.'
The partnership is significant as it aligns with Formycon's FYB4Growth strategy, which emphasizes geographic diversification, smart portfolio management, innovation, and cost efficiency. By leveraging OneSource's manufacturing facilities approved by global regulators including the US FDA and EMA, Formycon aims to ensure reliable supply while controlling costs. This is particularly important in the biosimilar market, where price competition is intense and manufacturing efficiency directly impacts affordability and patient access.
Formycon already markets three biosimilars—FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept—and has four pipeline candidates including FYB206/pembrolizumab and FYB208/dupilumab. The partnership with OneSource supports the advancement of these programs by adding scalable manufacturing capacity. For OneSource, the deal reinforces its role as a global CDMO for complex biologics, leveraging India's strengths in cost-effective production.
The implications of this announcement extend beyond the two companies. As biosimilars lose patent protection for blockbuster biologics representing over $200 billion in annual sales by 2032, partnerships like this are critical to expanding patient access. The global biosimilar market is projected to grow from $21 billion to over $74 billion by 2030. This partnership positions both companies to capture a share of that growth while delivering lower-cost alternatives to expensive biologic drugs.
More information about Formycon can be found at https://www.formycon.com/ and details on the FYB4Growth strategy at https://www.fyb4growth.com. OneSource's capabilities are detailed at www.onesourcecdmo.com.
